>
Aravive Inc logo

ARAV - Aravive Inc Share Price

$5.18 -0.3  -4.8%

Last Trade - 16/04/21

Sector
Healthcare
Size
Small Cap
Market Cap £73.6m
Enterprise Value £29.9m
Revenue £4.11m
Position in Universe 5129th / 6850
Bullish
Bearish
Unlock ARAV Revenue
Momentum
Relative Strength (%)
1m -40.8%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -65.3%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 40.0 1.37 4.75 5.69 3.11 5.61
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, AraviveInc revenues increased 20% to $5.7M. Net loss increased 68%to $30.5M. Revenues reflect an increase in demand for theCompany's products and services due to favorable marketconditions. Higher net loss reflects Research &administrative expenses increase of 37% to $17.1M (expense), Other Non-operating Income/Expense decrease from $2.5M(income) to $14K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ARAV Revenue Unlock ARAV Revenue

Net Income

ARAV Net Income Unlock ARAV Revenue

Normalised EPS

ARAV Normalised EPS Unlock ARAV Revenue

PE Ratio Range

ARAV PE Ratio Range Unlock ARAV Revenue

Dividend Yield Range

ARAV Dividend Yield Range Unlock ARAV Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
ARAV EPS Forecasts Unlock ARAV Revenue
Profile Summary

Aravive, Inc., formerly Versartis, Inc., is a clinical-stage biotechnology company. The Company is focused on developing therapies that target survival pathways for both solid tumors, as well as hematologic malignancies. Its primary therapeutic focus is the growth arrest-specific 6 (GAS6) - AXL receptor tyrosine kinase (AXL) pathway, where AXL receptor signaling promotes metastasis, cancer cell survival, resistance to treatments and immune suppression. The Company’s lead candidate, Aravive-S6 (AVB-S6)-500, is a GAS6 binding protein and AXL decoy receptor. It is a Fc -chimeric fusion protein designed to block the activation of the Growth arrest-specific 6 (GAS6)-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL. Its AXL decoy receptor is a protein based on the extracellular portion of AXL that binds its ligand GAS6, sequesters it from the native receptor and prevents AXLmediated signaling.

Directors
Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated December 10, 2008
Public Since March 20, 2014
No. of Shareholders: 29
No. of Employees: 17
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 19,659,860
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ARAV Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ARAV
Upcoming Events for ARAV
Tuesday 4th May, 2021 Estimate
Q1 2021 Aravive Inc Earnings Release
Monday 2nd August, 2021 Estimate
Q2 2021 Aravive Inc Earnings Release
Frequently Asked Questions for Aravive Inc
What is the Aravive Inc share price?

As of 16/04/21, shares in Aravive Inc are trading at $5.18, giving the company a market capitalisation of £73.6m. This share price information is delayed by 15 minutes.

How has the Aravive Inc share price performed this year?

Shares in Aravive Inc are currently trading at $5.18 and the price has moved by -49.85% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Aravive Inc price has moved by -65.44% over the past year.

What are the analyst and broker recommendations for Aravive Inc?

Of the analysts with advisory recommendations for Aravive Inc, there are there are currently 2 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Aravive Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Aravive Inc next release its financial results?

Aravive Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Aravive Inc dividend yield?

Aravive Inc does not currently pay a dividend.

Does Aravive Inc pay a dividend?

Aravive Inc does not currently pay a dividend.

When does Aravive Inc next pay dividends?

Aravive Inc does not currently pay a dividend.

How do I buy Aravive Inc shares?

To buy shares in Aravive Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Aravive Inc?

Shares in Aravive Inc are currently trading at $5.18, giving the company a market capitalisation of £73.6m.

Where are Aravive Inc shares listed? Where are Aravive Inc shares listed?

Here are the trading details for Aravive Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: ARAV
What kind of share is Aravive Inc?

Based on an overall assessment of its quality, value and momentum, Aravive Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Aravive Inc share price forecast 2021?

Shares in Aravive Inc are currently priced at $5.18. At that level they are trading at 0.334% discount to the analyst consensus target price of 0.00.

Analysts covering Aravive Inc currently have a consensus Earnings Per Share (EPS) forecast of -1.862 for the next financial year.

How can I tell whether the Aravive Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Aravive Inc. Over the past six months, the relative strength of its shares against the market has been -16.05%. At the current price of $5.18, shares in Aravive Inc are trading at -18.34% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Aravive Inc PE Ratio?

We were not able to find PE ratio data for Aravive Inc.

Who are the key directors of Aravive Inc?

Aravive Inc's management team is headed by:

Amato Giaccia - IND
Eric Zhang - IND
Vinay Shah - CFO
Gail McIntyre - PRE
Fredric Eshelman - CHM
Reshma Rangwala - OTH
Michael Rogers - DRC
Who are the major shareholders of Aravive Inc?

Here are the top five shareholders of Aravive Inc based on the size of their shareholding:

Eshelman Ventures LLC Corporation
Percentage owned: 19.36% (3.81m shares)
Eshelman (Fredric N) Individual Investor
Percentage owned: 14.62% (2.88m shares)
Tabibiazar (Raymond) Individual Investor
Percentage owned: 8.17% (1.61m shares)
Invus Public Equities Advisors, LLC Investment Advisor
Percentage owned: 6.67% (1.31m shares)
New Leaf Venture Partners Venture Capital
Percentage owned: 4.81% (946k shares)
Similar to ARAV
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.